Compare CCOI & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCOI | AQST |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 488.6M | 529.4M |
| IPO Year | 2002 | 2007 |
| Metric | CCOI | AQST |
|---|---|---|
| Price | $9.33 | $4.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $29.11 | $9.00 |
| AVG Volume (30 Days) | 1.7M | ★ 3.4M |
| Earning Date | 05-04-2026 | 05-01-2026 |
| Dividend Yield | ★ 0.34% | N/A |
| EPS Growth | ★ 11.21 | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $975,766,000.00 | $67,430,000.00 |
| Revenue This Year | $11.76 | $10.08 |
| Revenue Next Year | $6.09 | $49.60 |
| P/E Ratio | $16.66 | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $8.88 | $2.94 |
| 52 Week High | $45.69 | $7.55 |
| Indicator | CCOI | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 38.84 | 55.64 |
| Support Level | N/A | $4.03 |
| Resistance Level | $10.42 | $5.10 |
| Average True Range (ATR) | 0.75 | 0.26 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 20.05 | 48.53 |
Cogent carries over one-fifth of the world's internet traffic on its network, providing high-capacity services to businesses. Cogent's netcentric customers, which contribute nearly half of total revenue, include internet service providers and content providers, to which Cogent provides internet transit service. They hand traffic to Cogent in data centers and rely on Cogent to deliver it. About half of netcentric revenue is from outside the US. Cogent's corporate customers are in high-rise office buildings, where the firm provides two types of connections: dedicated internet access, which connects them to the internet, and virtual private networking. Cogent's corporate customers are exclusively in North America and account for about 40% of the firm's revenue.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.